The National Institute for Health and Care Excellence

Faster dementia diagnosis: inside UKRI's £80 million Dementia Challenge

From blood-based biomarkers to AI-powered tools, discover how 9 innovations are being tested in the NHS to speed up dementia ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable TA1195 30 September 2026 30 September 2026 Isatuximab with ...
National Institute for Health and Care Excellence

Our committees

Independent committees develop our recommendations. NICE committees are made up of people like you. They include experts in health and social care, people who use health and care services and carers.
National Institute for Health and Care Excellence

Epilepsies: diagnosis and management

This guideline has been updated and replaced by epilepsies in children, young people and adults ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Transurethral water jet ablation for lower urinary tract symptoms caused by benign prostatic hyperplasia

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.
National Institute for Health and Care Excellence

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...
National Institute for Health and Care Excellence

Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. This ...
National Institute for Health and Care Excellence

Intrapartum care

This guideline covers the care of pregnant women and pregnant trans and non-binary people and their babies during labour and immediately after birth. It focuses on women and pregnant people who give ...
National Institute for Health and Care Excellence

Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

There is a commercial access agreement for pembrolizumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact keiron.hughes@msd.com ...
National Institute for Health and Care Excellence

Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment

We have moved Health technology evaluation 20 to become HealthTech guidance 739. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...